Our current technical analysis of Biogen Inc (NASDAQ:BIIB)

BIIB
 Stock
  

USD 267.00  2.72  1.03%   

As many of us are excited about healthcare space, it is fair to go over Biogen Inc within current market trends. As we have suggested previously, Biogen is beginning its slip as investors shift to be more bearish due to the increased sector volatility. The company returns are correlated to returns on the market. As market fluctuates, the company is expected to follow. Strong forward indicators of the company may also suggest signals of long term gains for Biogen investors. Biogen Inc is scheduled to announce its earnings today. The stock is undergoing above-average trading activities.
Published over two months ago
View all stories for Biogen | View All Stories
The company's average rating is Hold from 29 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Biogen market sentiment investors' perception of the future value of Biogen. Let us look at a few aspects of Biogen technical analysis. Earning per share calculations of the firm is based on official Zacks consensus of 27 analysts regarding Biogen's future annual earnings. Given the historical accuracy of 90.68%, the future earnings per share of the company is estimated to be 19.17 with the lowest and highest values of 18.89 and 19.99, respectively. Please note that this consensus of annual earnings estimates for Biogen Inc is an estimate of EPS before non-recurring items and including employee stock options expenses.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Biogen Inc. In general, we focus on analyzing Biogen stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biogen's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Biogen's intrinsic value. In addition to deriving basic predictive indicators for Biogen, we also check how macroeconomic factors affect Biogen price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Biogen's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Biogen in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Biogen. Your research has to be compared to or analyzed against Biogen's peers to derive any actionable benefits. When done correctly, Biogen's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Biogen Inc.

How important is Biogen's Liquidity

Biogen financial leverage refers to using borrowed capital as a funding source to finance Biogen Inc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Biogen financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Biogen's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Biogen, but it might be worth checking our own buy vs. sell analysis

Exercise or conversion by Murphy Nicole of 825 shares of Biogen subject to Rule 16b-3

Legal trades by Biogen insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Biogen insider trading alert for exercise of restricted stock unit by Murphy Nicole, Head of Pharm Ops and Tech, on 3rd of August 2022. This event was filed by Biogen Inc with SEC on 2022-08-03. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at Biogen Variance

Biogen Inc has current Variance of 5.05. Variance is another measure of security risk that shows the amount of dispersion of equity returns around their mean value. Variance is calculated as the average squared deviations from the mean. Evaluating a set of investment alternatives one can use variance to help determine the volatility when purchasing a specific security. Similar to Standard Deviation, the variance is a measure of how far a set of numbers is spread out around its mean.

Variance is also a measure of stock volatility and can help determine the risk an investor might take on when purchasing a specific security. A relatively big variance indicates that the daily prices or returns are far from the mean and a small variance indicates that they are located around the mean.

Variance 
 = 
SUM(RET DEV)2 
 = 
5.05
SUM = Summation notation
RET DEV = Actual returns deviation over selected period
N = Number of points for the period
Let's now compare Biogen Variance to its closest peers:
BIIB
JNJ
BBI
WMT
CAT
BIIB5.048708160760098
JNJ1.46
BBI91.85
WMT4.25
CAT5.9

Our Biogen analysis suggests possible reversion in August

Current Skewness is up to -0.1. Price may slip again. Biogen Inc currently demonstrates below-average downside deviation. It has Information Ratio of 0.08 and Jensen Alpha of 0.19. However, we advise investors to further question Biogen Inc expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biogen's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biogen's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Biogen Implied Volatility

Biogen's implied volatility exposes the market's sentiment of Biogen Inc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Biogen's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Biogen stock will not fluctuate a lot when Biogen's options are near their expiration.

Our Final Take On Biogen

Whereas some other firms in the drug manufacturers—general industry are either recovering or due for a correction, Biogen may not be as strong as the others in terms of longer-term growth potentials. While some investors may not share our view, we believe it may be a good time to increase your existing holdings in Biogen. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Biogen.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Biogen Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com